Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study

被引：0
|
作者：
Liu, Jie
Deng, Yaotiao
Wang, Ying
Zhang, Jie
Li, Mei
Jiang, Yu
机构：
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[2] Chengdu Shang Jin Nan Fu Hosp, Chengdu, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Oncol, Chengdu, Peoples R China
[4] Chongqing Med Univ, Dept Oncol, Affiliated Hosp 1, Chongqing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11561
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
    Pacey, Simon
    Ratain, Mark J.
    Flaherty, Keith T.
    Kaye, Stanley B.
    Cupit, Lisa
    Rowinsky, Eric K.
    Xia, Chenghua
    O'Dwyer, Peter J.
    Judson, I. R.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 481 - 488
  • [22] Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
    Simon Pacey
    Mark J. Ratain
    Keith T. Flaherty
    Stanley B. Kaye
    Lisa Cupit
    Eric K. Rowinsky
    Chenghua Xia
    Peter J. O’Dwyer
    I. R. Judson
    Investigational New Drugs, 2011, 29 : 481 - 488
  • [23] Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
    Nakano, Kenji
    Hayakawa, Keiko
    Funauchi, Yuki
    Tanizawa, Taisuke
    Ae, Keisuke
    Matsumoto, Seiichi
    Tomomatsu, Junichi
    Ono, Makiko
    Taira, Shinichiro
    Nishizawa, Masatoshi
    Wang, Xiaofei
    Ohmoto, Akihiro
    Sato, Yasuyoshi
    Fukuda, Naoki
    Urasaki, Tetsuya
    Takahashi, Shunji
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (01) : 1 - 6
  • [24] Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS)
    Guo, Xi
    Zhou, Yuhong
    Zhuang, Rongyuan
    Zhang, Chenlu
    You, Yang
    Li, Wei
    Wang, Zhiming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group
    Woll, PJ
    Judson, I
    Lee, SM
    Rodenhuis, S
    Nielsen, OS
    Buesa, JM
    Lorigan, PC
    Leyvraz, S
    Hermans, C
    van Glabbeke, M
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) : 410 - 412
  • [26] A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft tissue sarcoma.
    Huang, Xin
    Ye, Zhaoming
    Li, Tao
    Wei, Yongzhong
    Wang, Shoufeng
    Liu, Yunxia
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Bailey, Howard H.
    Mahoney, Michelle R.
    Ettinger, David S.
    Maples, William J.
    Fracasso, Paula M.
    Traynor, Anne M.
    Erlichman, Charles
    Okuno, Scott H.
    CANCER, 2006, 107 (10) : 2462 - 2467
  • [28] A retrospective study to evaluate the safety and efficacy of anlotinib plus camrelizumab in management of advanced retroperitoneal sarcoma.
    Wu, Jianhui
    Qiu, Hui
    Lv, Ang
    Liu, Bonan
    Liu, Qiao
    Li, Chengpeng
    Liu, Daoning
    Wang, Zhen
    Tian, Xiuyun
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
    Chi, Yihebali
    Fang, Zhiwei
    Hong, Xiaonan
    Yao, Yang
    Sun, Ping
    Wang, Guowen
    Du, Feng
    Sun, Yongkun
    Wu, Qiong
    Qu, Guofan
    Wang, Shusen
    Song, Jianmin
    Yu, Jianchun
    Lu, Yongkui
    Zhu, Xia
    Niu, Xiaohui
    He, Zhiyong
    Wang, Jinwan
    Yu, Hao
    Cai, Jianqiang
    CLINICAL CANCER RESEARCH, 2018, 24 (21) : 5233 - 5238
  • [30] Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
    Liu, Zhiyong
    Wang, Xin
    Wang, Jiaqiang
    Zhang, Peng
    Li, Chao
    Wang, Bangmin
    Liu, Guancong
    Yao, Weitao
    FRONTIERS IN ONCOLOGY, 2022, 12
12345